ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION

Core Insights - Oragenics, Inc. has completed the first site initiation visit for its Phase IIa clinical trial of ONP-002 in Australia, marking the start of clinical trial operations at the first of three planned sites [2][3] - The remaining two sites are undergoing final administrative reviews before patient enrollment can begin, with expectations for completion in the near term [3][4] - The Phase IIa trial aims to evaluate the safety, tolerability, and preliminary clinical signals of ONP-002 in patients with acute concussion and mild traumatic brain injury [5][7] Company Overview - Oragenics, Inc. is a clinical-stage biotechnology company focused on brain-targeted therapeutics using proprietary intranasal delivery technology [11] - The lead candidate, ONP-002, is a first-in-class intranasal neurosteroid in Phase IIa development for treating concussion and mild traumatic brain injury, conditions affecting approximately 69 million people globally each year without approved pharmacological treatments [11] Clinical Trial Details - The Phase IIa trial is a randomized, placebo-controlled study with an enrollment target of 40 patients across three sites in Australia [9] - The primary endpoints include safety assessments, neurocognitive follow-up evaluations, and participant compliance/tolerability [9] - The first dose is to be administered within 12 hours of concussion onset, with the first site now operational and ready to enroll patients [9][6]